Neurogene
Neurogene's revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$78 million. The diluted share count rose 21.4%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Neurogene does
Neurogene is a clinical-stage biotechnology company, meaning its medicines are still being tested in people. It develops genetic medicines for rare neurological diseases that it says conventional gene therapy cannot address well. It was founded in 2018 and has no products approved for sale.
Its lead program, NGN-401, is for Rett syndrome, a severe, progressive disease of brain development. It uses a harmless virus, called an AAV, to carry a gene into the brain, and the company's EXACT technology, which uses microRNA-based circuits to keep the gene's output at a useful level. NGN-401 is given once, through a procedure that delivers it into the fluid-filled spaces of the brain. Neurogene is running a registrational trial, one meant to support an approval request, in females with Rett syndrome aged three and above. It expects to finish dosing in the second quarter of 2026.
It makes the clinical supplies itself at its own manufacturing facility in Houston, Texas. It has paid for its work with outside capital from selling stock and warrants and has not earned product revenue.
Its biggest risks, as it describes them
- It has a limited operating history, no products for sale and no completed clinical trials.
- It depends mainly on NGN-401, and its trial may not succeed.
- It will need substantial more capital, or may have to cut trials and programs.
- Its gene therapies use one type of AAV delivery vehicle, which carries its own risks.
- Trial participants may suffer side effects, and competitors are working on the same diseases.
Income statement
Neurogene lost money in fiscal 2025: a net loss of $90 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 142 | 82 | 197 | 312 | 269 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −28,258.5x | −4,631.9x | −6,883.8x | −20,665.6x |
| Current ratio | 16.7x | 12.7x | 8.7x | 20.8x | 16.6x |
| Quick ratio | 16.7x | 12.7x | 8.7x | 20.8x | 16.6x |
Cash flow
Projections
Project Neurogene's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Neurogene reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 6.15 | 14.53 | 11.14 |
| Accruals ratio | 9.1% | −1.6% | −4.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | — | — | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | — | — |
Compare
Put Neurogene side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Neurogene | FY25 | −100.0% | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 25 | — | — | — | — | 0 | 1 | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | −100.0% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 28 | 36 | 42 | 4 | 24 | 39 | 48 | 44 | 61 | 75 |
| Operating income | −38 | −51 | −33 | −71 | −34 | −61 | −56 | −56 | −83 | −103 |
| Net income | −37 | −50 | −32 | −69 | −33 | −61 | −55 | −36 | −75 | −90 |
| Diluted EPS (US$) | −1.96 | −2.14 | −1.34 | −2.57 | −0.64 | −1.10 | −1.04 | — | −4.28 | −4.24 |
| Diluted shares (millions) | 19 | 24 | 24 | 27 | 52 | 55 | 55 | — | 18 | 21 |
| Cash flow | ||||||||||
| Cash from operations | −30 | −45 | −32 | −15 | −25 | −48 | −53 | −51 | −71 | −77 |
| Capital expenditure | 1 | 0 | 0 | 1 | 2 | 3 | 2 | 0 | 1 | 1 |
| Free cash flow | −31 | −45 | −32 | −16 | −27 | −51 | −55 | −52 | −71 | −78 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 5 | 8 | 6 | 12 | 1 | 1 | 8 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 32 | 52 | 77 | 143 | 193 | 142 | 82 | 197 | 312 | 269 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 154 | 110 | 78 | 147 | 210 | 163 | 109 | 223 | 336 | 289 |
| Total liabilities | 10 | 11 | 5 | 5 | 19 | 20 | 11 | 36 | 25 | 24 |
| Shareholders' equity | 145 | 99 | 73 | 142 | 191 | −92 | −146 | 186 | 310 | 265 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −130.5% | — | — | — | — | — | −8,930.3% | — |
| Net margin | — | — | −126.3% | — | — | — | — | — | −8,123.7% | — |
| Free cash flow margin | — | — | −126.5% | — | — | — | — | — | −7,720.1% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −29.2% | −41.2% | −36.8% | −64.8% | −20.0% | −122.2% | — | −180.3% | −30.3% | −31.4% |
| Return on assets | −27.6% | −37.9% | −33.6% | −61.8% | −18.6% | −32.5% | −40.5% | −21.9% | −26.9% | −28.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |